Efficacy News and Research

RSS

Australian discovery could speed up SARS-CoV-2 vaccine development

To address this gap, researchers from Australia recently examined the relationship between levels of in vitro neutralization and the observed protection obtained from SARS-CoV-2 infection. They used data from 7 currently available vaccines and convalescent cohorts. Their research is published in the journal Nature Medicine.

22 May 2021

Modeling SARS-CoV-2 spike/human ACE2 complex identifies high-affinity variants that cause greater transmissibility

The study, published in the Journal of Molecular Biology, shows promise in detecting potential new variants that can cause the faster spread of COVID-19. The recent mutations and variants detected have caused the rapid spread of the infection in many countries.

21 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

Trial results show upadacitinib to be the most effective treatment for atopic dermatitis

The findings of a clinical trial by Trinity College Dublin researchers of treatment for atopic dermatitis have been published today in The Lancet journal (Friday, 21st May, 2021).

21 May 2021

Electrospun nanofibrous filters capture 99.9 percent of coronavirus aerosols, study finds

Researchers at The George Washington University and the University of California in the U.S. compared the efficacy of surgical and cotton masks, a neck gaiter, and electrospun nanofiber membranes to capture coronavirus aerosols and prevent airborne transmission.

21 May 2021

Masks and physical distancing could reduce SARS-CoV-2 spread to 1% among essential food plant workers, says study

The food supply is an essential service. Yet, workers in this industry are at high risk of acquiring infection with the novel coronavirus in their workplace unless proper mitigation measures are put in place. A new study, released as a preprint on the medRxiv* server, shows that the risk of infection may be reduced to less than 1% with proper precautions.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Covid-19 could continue to cause recurrent waves and deaths despite frequent vaccinations according to a new study from the University of East Anglia.

21 May 2021

Metal complexes against coronavirus

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 3.42 million deaths worldwide. Despite the fact that there are vaccines for SARS-CoV-2, the emergence of new variants and the lack of adequate treatments have encouraged the search for new ways to combat this disease more effectively.

21 May 2021

New study to develop program for infants at risk for health disparities

Many parents of young children can relate to the challenges of getting babies to eat healthy, whether babies throw food on the floor, refuse to eat healthy foods or only want to eat sugary snacks.

21 May 2021

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today.

21 May 2021

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

Recently, a team of researchers from various countries analyzed the unique variants of S proteins across six continents, including Africa, Asia, Oceania, Europe, South America, and North America. They wanted to characterize the unique S protein variants embedded in SARS-CoV-2 genomes infecting millions of people globally.

20 May 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

WHO’s new guidance sets essential standards to fight malaria, other vector-borne diseases

New guidance from the World Health Organization (WHO) sets essential standards to inform future research and development on genetically modified mosquitoes, particularly in addressing issues relating to ethics, safety, affordability and effectiveness.

20 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

Researchers in the UK have demonstrated the efficacy of the Pfizer-BioNTech and AstraZeneca vaccines against severe acute respiratory virus coronavirus 2 (SARS-CoV-2) at preventing death among older individuals with coronavirus disease 2019 (COVID-19).

20 May 2021

The effects of SARS-CoV-2 vaccination on pregnancy and birth

The severe impact of this infection has given rise to a study by Theiler et al. (2021), which investigated the effects of SARS-CoV-2 vaccination in pregnancy in order to examine the protection it could provide to combat the infection.

19 May 2021

Efficacy News and Research

Australian discovery could speed up SARS-CoV-2 vaccine development

Modeling SARS-CoV-2 spike/human ACE2 complex identifies high-affinity variants that cause greater transmissibility

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Trial results show upadacitinib to be the most effective treatment for atopic dermatitis

Electrospun nanofibrous filters capture 99.9 percent of coronavirus aerosols, study finds

Masks and physical distancing could reduce SARS-CoV-2 spread to 1% among essential food plant workers, says study

Facets of SARS-CoV-2 infection and animal models

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Metal complexes against coronavirus

New study to develop program for infants at risk for health disparities

Adaptimmune to report Phase 2 trial data on synovial sarcoma at ASCO congress

North America has 87% of all unique SARS-CoV-2 S protein variants in the NCBI database among six continents

Intranasal COVID-19 therapeutic shows promise in preclinical trials

WHO’s new guidance sets essential standards to fight malaria, other vector-borne diseases

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

SARS-CoV-2 vaccines from Pfizer-BioNTech and AstraZeneca reduce mortality among the elderly

The effects of SARS-CoV-2 vaccination on pregnancy and birth

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News